Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Kenei Furukawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5081-6417; OpenAlex author ID A5025740085. Sources: OpenAlex.

Their work

Papers
54 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 5 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 5 papers · 2022: 5 papers · 2023: 5 papers · 2024: 5 papers · 2025: 9 papers · 2026: 7 papers

Papers 50 of 54

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Co-author DOI 10.1002/wjs.70666↗
  2. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. First author DOI 10.1007/s00595-025-03188-7↗
  3. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  4. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  5. Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20340-w↗
  6. ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20399-5↗
  7. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  8. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. First author DOI 10.1007/s00595-024-02882-2↗
  9. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  10. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  11. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. First author DOI 10.1016/j.suronc.2024.102179↗
  12. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  13. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002416↗
  14. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  15. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  16. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  17. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. First author DOI 10.1016/j.pan.2024.01.003↗
  18. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  19. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  20. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  21. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. First author DOI 10.21873/anticanres.17229↗
  22. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  23. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  24. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  25. Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy. Co-author DOI 10.1186/s40792-023-01607-w↗
  26. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  27. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  28. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  29. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Co-author DOI 10.1093/carcin/bgac060↗
  30. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  31. Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. Co-author DOI 10.21873/anticanres.15972↗
  32. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Co-author DOI 10.1007/s00423-021-02166-0↗
  33. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  34. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. First author DOI 10.1007/s10147-021-01986-w↗
  35. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001767↗
  36. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  37. Splenic artery pseudoaneurysm following chemotherapy in a patient with pancreatic cancer: a case report. Co-author DOI 10.1007/s12328-020-01137-0↗
  38. The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cpr.12805↗
  39. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Co-author DOI 10.21873/anticanres.13952↗
  40. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  41. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Co-author DOI 10.1016/j.surg.2016.12.008↗
  42. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Co-author DOI 10.1007/s00268-016-3491-4↗
  43. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.034↗
  44. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. Co-author PMID 26254410↗
  45. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenoc… Co-author PMID 25202109↗
  46. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Co-author DOI 10.1007/s00595-012-0279-5↗
  47. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.019↗
  48. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… Co-author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  49. Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Co-author DOI 10.1097/mpa.0b013e31828cf976↗
  50. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Co-author PMID 24023348↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Shirai · 38 shared papers, 2014–2026 · strength 6.89
  2. Toru Ikegami · 33 shared papers, 2021–2026 · strength 6.83
  3. Koichiro Haruki · 40 shared papers, 2011–2026 · strength 6.41
  4. Shinji Onda · 25 shared papers, 2021–2026 · strength 5.02
  5. Masashi Tsunematsu · 22 shared papers, 2022–2026 · strength 4.91
  6. Michinori Matsumoto · 17 shared papers, 2021–2026 · strength 3.67
  7. Ryoga Hamura · 20 shared papers, 2018–2026 · strength 3.54
  8. Takeshi Gocho · 19 shared papers, 2012–2026 · strength 3.26
  9. Mitsuru Yanagaki · 14 shared papers, 2021–2026 · strength 3.05
  10. Tomohiko Taniai · 11 shared papers, 2021–2026 · strength 2.30
  11. Tadashi Uwagawa · 13 shared papers, 2021–2026 · strength 2.26
  12. Norimitsu Okui · 9 shared papers, 2023–2026 · strength 2.09
  13. Yoshiaki Tanji · 9 shared papers, 2023–2026 · strength 2.06
  14. Tadashi Uwagawa · 15 shared papers, 2011–2025 · strength 1.57
  15. Kyohei Abe · 8 shared papers, 2021–2025 · strength 1.52
  16. Taro Sakamoto · 7 shared papers, 2021–2026 · strength 1.42
  17. Hiroaki Shiba · 20 shared papers, 2011–2022 · strength 1.40
  18. Yosuke Igarashi · 5 shared papers, 2023–2026 · strength 1.18
  19. Katsuhiko K. Yanaga · 19 shared papers, 2011–2022 · strength 1.18
  20. Yuta Yamada · 4 shared papers, 2024–2026 · strength 1.01
  21. Yuki Fujiwara · 16 shared papers, 2011–2022 · strength 0.83
  22. Takashi Horiuchi · 7 shared papers, 2015–2022 · strength 0.64
  23. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  24. Hironori Shiozaki · 4 shared papers, 2021–2024 · strength 0.60
  25. Shuichi Fujioka · 3 shared papers, 2022–2025 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.